Asst. Prof. NAZİYE AK

Metrics

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

171

H-Index (WoS)

Citation (Scopus)

188

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Citation (Sobiad)

H-Index (Sobiad)

Total Citation Count

172

Project

Open Access

UN Sustainable Development Goals

Education

2022 - Present

Doctorate

Istinye University, Lisansüstü Eğitim Enstitüsü, Moleküler Onkoloji (DR), Turkey

2017 - 2020

Post Doctorate of Medicine

Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , Turkey

2012 - 2016

Expertise In Medicine

Istanbul University, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Turkey

2005 - 2011

Undergraduate

Istanbul University, Cerrahpaşa Tıp Fakültesi, İngilizce Tıp, Turkey

Dissertations

2016

Expertise In Medicine

MEME KANSERİNDE NEOADJUVAN KEMOTERAPİ YANITINI PREDİKTE EDEN PATOLOJİK FAKTÖRLER

Istanbul University, Cerrahpaşa Tıp Fakultesi, İç Hastalıkları Anabilim Dalı

2016

Expertise In Medicine

Meme kanserinde neoadjuvan kemoterapi yanıtını predikte eden patolojik faktörler

İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine

Foreign Languages

B1 Intermediate

English

Certificates, Courses and Trainings

2018

PSİKOONKOLOJİ 2. DÜZEY KLİNİSYEN EĞİTİMİ

Education Management and Planning

PSİKONET-UZM. PSİKOLOG ESRA SAVAŞ KAPLAN BİREYSEL EĞİTİMİ

2017

AİLE DANIŞMANLIĞI

Education Management and Planning

ULUDAĞ ÜNİVERSİTESİ-UZAKTAN EĞİTİM

2017

İMMUNOONKOLOJİ KURSU

Health&Medicine

TÜRK TIBBİ ONKOLOJİ DERNEĞİ

2017

PSİKOONKOLOJİ 1. DÜZEY KLİNİSYEN EĞİTİMİ

Education Management and Planning

PSİKONET-UZM. PSİKOLOG ESRA SAVAŞ KAPLAN BİREYSEL EĞİTİMİ

Research Areas

Medicine

Internal Medicine Sciences

Internal Diseases

Oncology

Health Sciences

Research Areas Based on Academic Activities

Avesis Research Areas

WoS Research Areas

Scopus Research Areas

Academic Positions

2024 - Present

Assistant Professor

Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı

2023 - 2024

Associate Professor

Istanbul Bilim University

2017 - 2020

Research Assistant

Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences

2012 - 2016

Research Assistant

İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine

Articles

2026

1. CT-based radiomics for predicting PD-L1 expression status in non-small cell lung cancer using a hybrid machine learning model

Durmaz M., Emec M., KIZILDAĞ YIRGIN İ., ILGIN C., Kaval G., Bunul I., et al.

Clinical Imaging , vol.132, 2026 (SCI-Expanded, Scopus)

2026

2. Prognostic Role of Endocan and Platelet-Derived Growth Factor Isoforms in Metastatic Colorectal Cancer

Yildiz A., Ahmed M. A., Azizy A., Çokgezer S., Ulufer B., Soydinc H., et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , vol.27, no.6, 2026 (SCI-Expanded, Scopus)

2026

3. Evaluating Comorbidity Scores in Geriatric Ovarian Cancer: A Retrospective Cohort Analysis

ÇOKGEZER S., AK N., Senkal M., Safaraliyeva A., TAŞTEKİN D., SAİP P. M.

Medicina (Lithuania) , vol.62, no.1, 2026 (SCI-Expanded, Scopus)

2025

4. Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

Ellez H. İ., SEMİZ H. S., EKİNCİ F., ERDOĞAN A. P., Kuş F., Karataş F., et al.

Journal of Bone Oncology , vol.55, 2025 (SCI-Expanded, Scopus)

2025

5. Association Between Adipose Tissue Distribution and Survival in Recurrent Ovarian Cancer Patients Treated With Anti-VEGF Therapy: A Retrospective CT-Based Analysis

Cokgezer S., Senkal M., Safaraliyeva A., Kose H., KIZILDAĞ YIRGIN İ., SAİP P. M., et al.

Journal of Obstetrics and Gynaecology Research , vol.51, no.11, 2025 (SCI-Expanded, Scopus)

2025

6. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

ŞENDUR M. A. N., Hizal M., Cakar B., AKTEPE O. H., Eraslan E., ARIK Z., et al.

BMC CANCER , vol.25, no.1, 2025 (SCI-Expanded, Scopus)

2025

7. Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study

Baser M. N., Demir B., Serin Ozel G., Dogu G. G., Karakaya S., UGAR M., et al.

Medicina (Lithuania) , vol.61, no.7, 2025 (SCI-Expanded)

2025

8. Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial.

Özkurt E., Ordu C., Özmen T., Ilgun A. S., Soybir G., Celebi F., et al.

World journal of surgery , 2025 (SCI-Expanded)

2025

9. Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative Analysis

Kalkan N., Ucar G., Esen S., Bardakci M., Aydin S., Celebi A., et al.

NIGERIAN JOURNAL OF CLINICAL PRACTICE , vol.28, no.2, pp.212-218, 2025 (SCI-Expanded, Scopus)

2025

10. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Dülgar Ö., Türker S., Başaran G., Araz M., Sümbül A. T., Çağlayan D., et al.

Journal of Chemotherapy , vol.37, no.4, pp.334-340, 2025 (SCI-Expanded, Scopus)

2024

11. Outcomes of reconstructive techniques in breast cancer using BCCT. core software

Kurt S., İlgün A. S., Özkurt E., Soybir G., Alço G., Ünal Ç., et al.

World Journal of Surgical Oncology , vol.22, no.1, 2024 (SCI-Expanded, Scopus)

2024

12. Prognostic Value of p16^INK4A and Ki67 Co-expression in Patients with Vaginal Intraepithelial Neoplasia

Minareci Y., AK N., Bayram A., Tosun O. A., Murdan R., Onder S., et al.

INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY , vol.22, no.2, 2024 (ESCI)

2024

13. The evaluation of miR-1181 and miR-4314 as serum microRNA biomarkers for epithelial ovarian cancer diagnosis and prognosis.

Minareci Y., Ak N., Sozen H., Tosun O. A., Kucukgergin C., Aydin F., et al.

Molecular biology reports , vol.51, no.1, pp.515, 2024 (SCI-Expanded, Scopus)

2024

14. The Relationship of Pathological Response and Visceral Muscle and Fat Volume in Women With Breast Cancer Who Received Neoadjuvant Chemotherapy

Tapan T. K., Çelebi F., Yaghouti K., Aǧaçayak F., Ilgün S., Soybir G., et al.

European Journal of Breast Health , vol.20, no.2, pp.117-121, 2024 (ESCI, Scopus, TRDizin)

2024

15. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., et al.

Turkish Journal of Medical Sciences , vol.54, no.1, pp.229-238, 2024 (SCI-Expanded, Scopus, TRDizin)

2024

16. The Effect of Adjuvant Therapies for Recurrence in Stage I Breast Cancer Patients: A Single Centre Experience

Doğan İ., Khanmammadov N., Aydin E., PAKSOY N., Ferhatoğlu F., AK N., et al.

Turk Onkoloji Dergisi , vol.39, no.3, pp.257-264, 2024 (ESCI, Scopus, TRDizin)

2023

17. Autoimmune hemolytic anemia associated with clear cell renal carcinoma: A case report

Güven S., Ak N.

Journal of Current Hematology & Oncology Research , vol.3, no.1, pp.102-103, 2023 (Peer-Reviewed Journal)

2023

18. Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients

DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., et al.

Journal of Cancer Research and Clinical Oncology , vol.149, no.16, pp.14833-14841, 2023 (SCI-Expanded, Scopus)

2023

19. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., et al.

The oncologist , vol.28, no.10, pp.875-884, 2023 (SCI-Expanded, Scopus)

2023

20. MICRORNA 1181 AND 4314 AS PROMISING BIOMARKERS FOR EPITHELIAL OVARIAN CANCER DIAGNOSIS AND PROGNOSIS

MİNARECİ Y., AK N., SÖZEN H., Tosun O. A., KÜÇÜKGERGİN C., AYDIN F., et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , 2023 (SCI-Expanded, Scopus)

2023

21. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.8, pp.4141-4148, 2023 (SCI-Expanded)

2023

22. Central nervous system metastasis in gynecologic cancers: Seeking the prognostic factors

Minareci Y., AK N., Tosun O. A., Sozen H., SAİP P. M., Topuz S., et al.

Journal of Cancer Research and Therapeutics , vol.19, 2023 (SCI-Expanded, Scopus)

2023

23. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine

DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.

European Journal of Breast Health , vol.19, no.2, pp.128-133, 2023 (Scopus, TRDizin)

2023

24. MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification

Unal C., Ozmen T., Ilgun A. S., Ordu C., Ozkurt E., AK N., et al.

BREAST CANCER-TARGETS AND THERAPY , vol.15, pp.659-669, 2023 (SCI-Expanded)

2023

25. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., et al.

JOURNAL OF CHEMOTHERAPY , vol.35, no.2, pp.142-149, 2023 (SCI-Expanded, Scopus)

2023

26. Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital

FERHATOĞLU F., Kapağan T., Paksoy N., Ak N., Medetalibeyoğlu A., Şenkal N., et al.

Turk Onkoloji Dergisi , vol.38, no.1, pp.82-91, 2023 (ESCI, Scopus, TRDizin)

2023

27. Clinicopathologic characteristics and prognostic factors in patients with male breast cancer: A single tertiary center experience

Dogan I., AYDIN E., AK N., ÖZKURT S., İBİŞ K., ŞÜKRÜOĞLU ERDOĞAN Ö., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.19, no.7, pp.1887-1892, 2023 (SCI-Expanded, Scopus)

2022

28. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., et al.

Medicine (United States) , vol.101, no.45, 2022 (SCI-Expanded, Scopus)

2022

29. The Predictive Importance of Body-Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

Emirzeoglu L., Arici S., Sahin A. B., Ocak B., Ak N., Ay S., et al.

BREAST CARE , 2022 (SCI-Expanded, Scopus)

2022

30. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Hizal M., Bilgin B., Paksoy N., Kilickap S., Atci M. M., KAHRAMAN S., et al.

FUTURE ONCOLOGY , vol.18, pp.2573-2582, 2022 (SCI-Expanded)

2022

31. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)

2022

32. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.

Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022 (SCI-Expanded, Scopus)

2022

33. Recurrent autoimmune encephalitis related to immune checkpoint inhibitors

Ser M. H., Samanci N. S., Naziye A. K., Aydiner A., Ozkara C.

EPILEPTIC DISORDERS , vol.24, no.3, pp.609-613, 2022 (SCI-Expanded)

2022

34. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study

Cil I., Kucukarda A., Atci M. M., Secmeler S., Paksoy N., Ferhatoglu F., et al.

TUMORI JOURNAL , vol.108, no.1, pp.19-25, 2022 (SCI-Expanded)

2022

35. Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer

Minareci Y., Sozen H., Ak N., Tosun O. A., Saip P., Salihoglu M. Y., et al.

CHEMOTHERAPY , vol.67, pp.1-11, 2022 (SCI-Expanded, Scopus)

2022

36. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.

Bosnian Journal of Basic Medical Sciences , vol.22, no.5, pp.818-825, 2022 (SCI-Expanded)

2022

37. Predictors of high-grade residual disease after repeat conization in patients with positive surgical margins

Minareci Y., AK N., Tosun O. A., Sozen H., Disci R., Topuz S., et al.

Ginekologia polska , vol.93, no.12, pp.962-967, 2022 (Scopus)

2022

38. Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey

Karabulut S., DOĞAN İ., USUL AFŞAR Ç., Karabulut M., Ak N., Duran A., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.1, pp.127-134, 2022 (SCI-Expanded, Scopus)

2022

39. Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report.

Paksoy N., Erdem S., Karaca M., Ak N., Pehlivan M., Yirgin İ., et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , vol.28, no.1, pp.215-221, 2022 (SCI-Expanded, Scopus)

2021

40. Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer

Ak N., Vatansever S.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS , vol.46, no.6, pp.1787-1791, 2021 (SCI-Expanded, Scopus)

2021

41. Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience

Ferhatoglu F., Amirov F., Ozkan B., Kara M., Toker A., Ak N., et al.

ONCOLOGY RESEARCH AND TREATMENT , no.11, pp.590-600, 2021 (SCI-Expanded, Scopus)

2021

42. Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center

Ak N., Toker A., Kara M., Ozkan B., Ulker M., Kaba E., et al.

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY , vol.29, no.4, pp.487-495, 2021 (SCI-Expanded, Scopus, TRDizin)

2021

43. Nivolumab treatment for metastatic thymic epithelial tumors.

Ak N., Aydiner A.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , vol.27, pp.1710-1715, 2021 (SCI-Expanded, Scopus)

2021

44. Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment

Karanlik H., CABIOĞLU N., Oprea A. L., ÖZGÜR İ., AK N., AYDINER A., et al.

BREAST CARE , vol.16, no.5, pp.468-474, 2021 (SCI-Expanded, Scopus)

2021

45. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Oner G., Onder S., Karatay H., Ak N., Tukenmez M., Muslumanoglu M., et al.

WORLD JOURNAL OF SURGICAL ONCOLOGY , vol.19, no.1, 2021 (SCI-Expanded, Scopus)

2021

46. Skeletal system as a rare metastatic site in patients with ovarian carcinoma

Ak N., Minareci Y., Saip P.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , vol.31, no.8, pp.1125-1131, 2021 (SCI-Expanded, Scopus)

2021

47. Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.

Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded, Scopus)

2021

48. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.

JOURNAL OF BUON , vol.26, no.3, pp.819-829, 2021 (SCI-Expanded)

2021

49. Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.

Ferhatoglu F., Paksoy N., Dogan I., Ak N., Pehlivan M., Ekenel M., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded, Scopus)

2021

50. Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer

AK N., PAKSOY N., VELİDEDEOĞLU M., TURNA Z. H., DEMİRELLİ F. H.

Journal of oncological sciences , vol.7, no.2, pp.42-49, 2021 (Scopus)

2021

51.

MINARECI Y., TOSUN Ö., Ak N., SÖZEN H., TOPUZ S., SALIHOGLU M. Y.

Kocaeli Tıp Dergisi , vol.10, no.3, pp.217-224, 2021 (Peer-Reviewed Journal)

2021

52. Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?

Celik E., Kizildag Yirgin I., Goksever Celik H., Engin G., Sozen H., Ak N., et al.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH , vol.47, no.2, pp.560-569, 2021 (SCI-Expanded, Scopus)

2021

53. "Door to Treatment" Outcomes of Cancer Patients during the COVID-19 Pandemic

Ak N., Vatansever S.

CHEMOTHERAPY , vol.65, no.5-6, pp.141-146, 2021 (SCI-Expanded)

2021

54. Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma

Naziye A. K., Paksoy N., Ferhatoglu F., Aydin E., Dogan I., Bektas E., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.36, pp.438-445, 2021 (ESCI)

2021

55. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al.

CANCER INVESTIGATION , vol.39, no.6-7, pp.473-481, 2021 (SCI-Expanded, Scopus)

2021

56. Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Ak N., Ciftci R., Cabioglu N., Aydiner A.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.36, no.2, pp.215-221, 2021 (ESCI, Scopus, TRDizin)

2021

57. Nectin-2 and Nectin-4 Adhesion Molecules in Patients with Breast Cancer

Ak N., Serilmez M., Ucuncu M. Z., Bademler S., Vatansever S.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.36, no.2, pp.165-170, 2021 (ESCI, Scopus, TRDizin)

2020

58. Rapid drug desensitization for platinum-based chemotherapy drugs significantly increases peripheral blood IL-10 levels

Tüzer C., Sarı M., Aktaş Ç., Ak N., Büyüköztürk S., Çolakoğlu B., et al.

ALLERGY , vol.75, no.11, pp.2942-2946, 2020 (SCI-Expanded, Scopus)

2020

59. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., et al.

EUROPEAN JOURNAL OF CANCER CARE , vol.29, no.6, 2020 (SCI-Expanded, SSCI, Scopus)

2019

60. IS CHEMOTHERAPY BETTER FOR EARLY STAGE HIGH RISK HISTOLOGIC TYPES OF ENDOMETRIAL CANCER

ÇELİK E. G., AK N., SÖZEN H., SAİP P. M., TOPUZ S.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , vol.29, 2019 (SCI-Expanded, Scopus)

2019

61. Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center

Ak N., Toker A., Bayraktar S., Ozkan B., Ülker M. B. C., Dagoglu N., et al.

JOURNAL OF THORACIC ONCOLOGY , no.10, 2019 (SCI-Expanded, Scopus)

2019

62. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

Eralp Y., Ak N., Yilmazbayhan D., Ozkan B., Ferhatoglu F., Demirkazik A., et al.

JOURNAL OF THORACIC ONCOLOGY , vol.14, no.10, 2019 (SCI-Expanded, Scopus)

2019

63. Feasibilty of sentinel lymph node biopsy in patients with node-positive inflammatory breast cancer who responded to neoadjuvant systemic treatment

OPREA A. -., Ak N., Saip P., Onder S., Bademler S., Gulluoglu B. M., et al.

BREAST , vol.44, 2019 (SCI-Expanded)

2019

64. Survival Impact of Optimal Surgical Cytoreduction in Recurrent Epithelial Ovarian Cancer with Brain Metastasis.

Keskin S., Kucucuk S., Ak N., ATALAR B., Sari M., Sozen H., et al.

Oncology research and treatment , vol.42, no.3, pp.101-106, 2019 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences

2025

1. Cerrahi Sonrası İntrahepatik Kolanjiyokarsinom Nüksünü Etkileyen Faktörler: Refere BirMerkezin 25 Yıllık Deneyimi

Serin K. R., Şal O., Göksoy B., Uzunyolcu G., Berker N., Büyük M., et al.

17. Türk HPB Cerrahi Kongresi, Antalya, Turkey, 29 October - 01 November 2025, pp.267, (Summary Text)

2023

2. MICRORNA 1181 AND 4314 AS PROMISING BIOMARKERS FOR EPITHELIAL OVARIAN CANCER DIAGNOSIS AND PROGNOSIS

Minareci Y., Ak N., Sözen H., Tosun Ö., Küçükgergin C., Aydın A. F., et al.

ESGO 2023 European Congress on Gynaecological Oncology, İstanbul, Turkey, 28 September - 01 October 2023, vol.33, pp.242, (Summary Text)

2021

3. Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer

DOĞAN İ., Aydın E., PAKSOY N., FERHATOĞLU F., AK N., İBİŞ K., et al.

ASCO 2021, United States Of America, 04 June 2021, (Summary Text)

2020

4. Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience

DOĞAN İ., AYDIN E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., et al.

ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 November 2020, vol.31, (Summary Text)

2019

5. Does nutritional status affect treatment tolerability, response and survival in metastatic gastric cancer patients? Results of prospective multicenter study

Karabulut S., Dogan I., Ak N., Afsar C. U., Karabulut M., Tastekin D.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.305, (Summary Text)

2019

6. Does nutritional status affect treatment tolerability, response and survival in metastatic gastric cancer patients? Results of prospective multicenter study

AK N.

European Society for Medical Oncology Congress 2019, Barcelona, Spain, 27 September - 01 October 2019, pp.424-430, (Summary Text)

2019

7. OUTCOMES OF THYMOMA AND DETERMINANTS OF SURVIVAL: 16 YEARS EXPERIENCE OF A TERTIARY CANCER CENTER

AK N.

World Conferrence of Lung Cancer, Barcelona, Spain, 7 - 10 September 2019, pp.1095-1096, (Summary Text)

2019

8. THE ROLE ADJUVANT CHEMOTHERAPY IN RESECTED STAGE 1 NSCLC WITH HIGH RISK FACTORS: A TURKISH ONCOLOGY GROUP STUDY

AK N.

World Conferrence of Lung Cancer 2019, Barcelona, Spain, 7 - 10 September 2019, pp.933-934, (Summary Text)

2019

9. Rapid drug desensitization for platinum-based chemotherapy drugs significantly increases peripheral blood IL-10 levels

Tuzer O. C., Sari M., Aktas E., Ak N., Buyukozturk S., Colakoglu B., et al.

Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Lisbon, Portugal, 1 - 05 June 2019, vol.74, pp.737-738, (Summary Text)

2019

10. Significance of adiposity in endometrial cancer prognosis.

KIZILDAĞ YIRGIN İ., ENGİN G., ÇELİK E., TOPUZ S., AK N., SAİP P.

Türk manyetik rezonans derneği.24.Uluslararası katılımlı yıllık bilimsel toplantısı. 2019, Ankara, Turkey, 25 - 27 April 2019, (Full Text)

2018

11. Platin ile hızlı desensitizasyonun sitokin düzeylerine etkisi P -29

Tüzer Ö. C., Sarı M., ÇETİN E., Ak N., BÜYÜKÖZTÜRK S., ÇOLAKOĞLU B., et al.

XXV. Ulusal Alerji ve Klinik İmmünoloji Kongresi, Antalya, Turkey, 17 - 21 November 2018, pp.111, (Full Text)

2013

12. IVIG sonrası akut miyokard enfarktüsü gelişen iki ITP olgusu

BAVUNOĞLU I., EYİCE D., AK N., ELVERDI T., EŞKAZAN A. E., AR M. C., et al.

39. Ulusal Hematoloji Kongresi, Antalya, Turkey, 23 - 26 October 2013, no.261, pp.277-278, (Full Text)

2012

13. IVIG sonrası akut miyokard enfarktüsü gelişen iki ITP olgusu

BAVUNOĞLU I., EYİCE D., AK N., ELVERDI T., EŞKAZAN A. E., AR M. C., et al.

38. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October - 03 November 2012, no.261, pp.277-278, (Full Text)

Books

2020

1. Göğüs duvarı tümörlerinde kemoterapi

AK N., Keskin S.

in: Göğüs duvarı hastalıkları ve cerrahisi, Ali Cevat Kutluk, Soner Gürsoy, Editor, Türkiye Solunum Araştırmaları derneği, pp.209-2013, 2020

2019

2. Endometrium Kanserleri

AK N.

in: Klinik Çalışmalarla Onkolojide Hedefli Tedaviler, CİHAN S, GEREDELİ Ç, DEMİR C., Editor, Tıbbi Yayınlar Merkezi, İstanbul, pp.113-122, 2019

2019

3. Systemic Treatment Drugs/Regimens and Dose Modifications

AK N.

in: Breast Disease, Aydiner A., Igci A., Soran A., Editor, Springer, Cham, Isviçre, pp.789-801, 2019

2019

4. Systemic Treatment Drugs/Regimens and Dose Modifications

AK N., AYDINER A.

in: Breast Disease, Adnan Aydiner, Abdullah Igci, Atilla Soran, Editor, Springer Cham, pp.789-801, 2019

2019

5. Timus hastalıklarında kemoterapi

AK N., AYDINER A.

in: Timus hastalıkları ve tedavisi, Dr. Koray Dural, Dr. Berker Özkan, Dr. Berkant Özpolat, Editor, Ankara Nobel Tıp Kitabevleri, Ankara, pp.180-185, 2019

2018

6. Systemic Treatment Drugs and Regimens

AK N.

in: Breast Cancer A Guide to Clinical Practice, Aydiner A, Igci A, Soran A., Editor, Springer International Publishing, Copyright Holder Springer Nature Switzerland Ag, pp.587-608, 2018

2018